Curcumin: From ancient medicine to current clinical trials

By H. Hatcher, R. Planalp, J. Cho, Frank M. Torti, Suzy V. Torti. Cellular and Molecular Life Sciences, 2008

1,826 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Herbal extracts and phytochemicals: plant secondary metabolites and the enhancement of human brain function. (2011, background): “These include assessments of its efficacy in the treatment of AD as a monotherapy and in combination with GB (232).”
The cytoprotective role of the Keap1–Nrf2 pathway (2011, background): “The double-Michael acceptor curcumin inhibits tumour development in animal models of oral, gastric, intestinal, colonic, hepatic and cutaneous carcinogenesis (reviewed in Surh and Chun 2007; Hatcher et al. 2008).”
Targets of curcumin (2011, background): “Consistent with the growing in vitro and in vivo evidence of curcumin’s anti-inflammatory and anti-cancer properties, disease targets include rheumatoid arthritis [244], postoperative inflammation [245], idiopathic inflammatory orbital pseudotumors [246], Alzheimer’s disease, multiple myeloma [247],”